KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $721000.0.

  • Bionano Genomics' Change in Accured Expenses rose 8582.47% to $721000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 7289.05%. This contributed to the annual value of -$2.0 million for FY2024, which is 2101.51% up from last year.
  • Per Bionano Genomics' latest filing, its Change in Accured Expenses stood at $721000.0 for Q3 2025, which was up 8582.47% from -$1.3 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Change in Accured Expenses high stood at $3.5 million for Q3 2022, and its period low was -$5.3 million during Q2 2024.
  • Its 5-year average for Change in Accured Expenses is -$67947.4, with a median of -$443000.0 in 2022.
  • As far as peak fluctuations go, Bionano Genomics' Change in Accured Expenses surged by 68010.9% in 2021, and later tumbled by 107310.34% in 2022.
  • Over the past 5 years, Bionano Genomics' Change in Accured Expenses (Quarter) stood at -$145000.0 in 2021, then plummeted by 1073.1% to -$1.7 million in 2022, then crashed by 105.11% to -$3.5 million in 2023, then skyrocketed by 91.34% to -$302000.0 in 2024, then skyrocketed by 338.74% to $721000.0 in 2025.
  • Its Change in Accured Expenses stands at $721000.0 for Q3 2025, versus -$1.3 million for Q2 2025 and -$488000.0 for Q1 2025.